{"id":"zyn002-transdermal-gel","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Application site reactions"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2109015","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of cannabidiol is not fully understood, but it is believed to modulate the activity of various receptors in the brain and body, leading to its therapeutic effects. This may involve the inhibition of inflammatory responses, the reduction of pain and anxiety, and the improvement of mood. Further research is needed to fully elucidate the mechanisms by which ZYN002 exerts its effects.","oneSentence":"ZYN002, a transdermal gel formulation of cannabidiol, is thought to exert its therapeutic effects through its action on the endocannabinoid system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:29.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seizure disorders"}]},"trialDetails":[{"nctId":"NCT05149898","phase":"PHASE2","title":"Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2020-02-19","conditions":"22Q11.2 Deletion Syndrome","enrollment":20},{"nctId":"NCT06930872","phase":"PHASE1","title":"Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2025-06-06","conditions":"Drug Interaction","enrollment":29},{"nctId":"NCT04977986","phase":"PHASE3","title":"Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome","status":"COMPLETED","sponsor":"Zynerba Pharmaceuticals, Inc.","startDate":"2021-09-13","conditions":"Fragile X Syndrome","enrollment":215},{"nctId":"NCT03802799","phase":"PHASE2, PHASE3","title":"Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS","status":"ENROLLING_BY_INVITATION","sponsor":"Zynerba Pharmaceuticals, Inc.","startDate":"2018-11-09","conditions":"Fragile X Syndrome","enrollment":550},{"nctId":"NCT03614663","phase":"PHASE2, PHASE3","title":"Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)","status":"COMPLETED","sponsor":"Zynerba Pharmaceuticals, Inc.","startDate":"2018-06-12","conditions":"Fragile X Syndrome","enrollment":212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)"],"phase":"phase_3","status":"active","brandName":"ZYN002 - transdermal gel","genericName":"ZYN002 - transdermal gel","companyName":"Zynerba Pharmaceuticals, Inc.","companyId":"zynerba-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ZYN002, a transdermal gel formulation of cannabidiol, is thought to exert its therapeutic effects through its action on the endocannabinoid system. Used for Seizure disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}